GT바이오파마 (GTBP) 주가

GT바이오파마(GTBP)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.30 (-0.47%), 시가총액 $0.01B, 52주 범위 $0.27 ~ $3.80.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed

핵심 지표

• 현재가: $0.30 (-0.47%)
• 시가총액: $0.01B
• 52주 최저~최고: $0.27 ~ $3.80
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

GT바이오파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

GT바이오파마 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 2.31
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문